Biofrontera

Contact
biofrontera.com
+4921487632-22

Biofrontera AG

Hemmelrather Weg 201
51377 Leverkusen
Germany
+4921487632-22
biofrontera.com
Contact
Profile News
Contact

About Biofrontera

Biofrontera AG specializes in the development of pharmaceutical products in the field of dermatology. The company is characterized by a broad, market-oriented product portfolio and comfortable liquidity. Biofrontera is listed on the regulated market of the Düsseldorf Stock Exchange and other German stock exchanges under the ticker symbol B8F and the ISIN number DE0006046113.

Read more about Biofrontera

Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of company presentation. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.

Read more
Facts about Biofrontera
  • Focus : Manufacturer
  • Industry : Pharma

News about Biofrontera

Biofrontera

22-Feb-2024 | research and development

Biofrontera transfers clinical research to the U.S.

"We can be much more flexible in our strategy to expand our market presence in Europe thanks to the newly defined cost structure"

Read news
Biofrontera

20-Dec-2011 | research and development

European Commission authorizes EU-wide marketing and distribution of Biofrontera's Ameluz

Biofrontera was informed by the European Commission that its product Ameluz® (in development called BF-200 ALA) was approved for distribution throughout ...

Read news
Biofrontera

26-Oct-2011 | research and development

The EMA recommends approval of Biofrontera's BF-200 ALA

The European Medicines Agency (EMA) issued a favourable opinion on Biofrontera's marketing approval application for its new medicinal product BF-200 ALA ...

Read news
Biofrontera

31-Jan-2011 | research and development

Positive review of the European Medicines Agency in the approval process of Biofrontera's BF-200 ALA

Biofrontera has received a positive interim report of the responsible committee of the European Medicines Agency (EMA) in the ongoing centralized approval ...

Read news
Biofrontera

23-Dec-2010 | research and development

Biofrontera received official review of its drug approval dossier for BF-200 ALA

Biofrontera announces that the European Medical Agency (EMA) has sent the official summaries and preliminary questions of the reviewers (rapporteurs) about ...

Read news
Biofrontera

04-Oct-2010 | research and development

Validation of the dossier for drug approval of Biofrontera's BF-200 ALA successful

Biofrontera AG announced that the European Medical Agency EMA has confirmed the successful validation of the drug approval dossier for BF-200 ALA. With ...

Read news
Biofrontera

16-Aug-2010 | business & finance

Biofrontera received manufacturing and distribution license

Biofrontera AG announces, that its subsidiary Biofrontera Pharma GmbH received the permission to import pharmaceutical products, clear them for European ...

Read news
Biofrontera

07-Dec-2009 | research and development

Biofrontera: Phase III data of BF-200 ALA demonstrate superiority against Metvix

Biofrontera announced that the company has today been informed about preliminary results of the final pivotal phase III trial with its leading drug ...

Read news
Show more news about Biofrontera

Here you will find Biofrontera AG